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A B S T R A C T
A systematic nomenclature for allergens originated in the early 1980s, when few protein allergens had been
described. A group of scientists led by Dr. David G. Marsh developed a nomenclature based on the Linnaean
taxonomy, and further established the World Health Organization/International Union of Immunological
Societies (WHO/IUIS) Allergen Nomenclature Sub-Committee in 1986. Its stated aim was to standardize the
names given to the antigens (allergens) that caused IgE-mediated allergies in humans. The Sub-Committee first
published a revised list of allergen names in 1986, which continued to grow with rare publications until 1994.
Between 1994 and 2007 the database was a text table online, then converted to a more readily updated website.
The allergen list became the Allergen Nomenclature database (www.allergen.org), which currently includes
approximately 880 proteins from a wide variety of sources. The Sub-Committee includes experts on clinical and
molecular allergology. They review submissions of allergen candidates, using evidence-based criteria developed
by the Sub-Committee. The review process assesses the biochemical analysis and the proof of allergenicity
submitted, and aims to assign allergen names prior to publication. The Sub-Committee maintains and revises the
database, and addresses continuous challenges as new “omics” technologies provide increasing data about po-
tential new allergens. Most journals publishing information on new allergens require an official allergen name,
which involves submission of confidential data to the WHO/IUIS Allergen Nomenclature Sub-Committee, suf-
ficient to demonstrate binding of IgE from allergic subjects to the purified protein.
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1. Introduction
Early reports of adverse health problems that are thought to re-
present allergies and asthma date back more than 3000 years from
Egypt, Rome and China, but these are not well documented. Likely
cases of allergy to various inhalation sources or insect bites or stings are
often dismissed as the nature and cause of the reactions were unknown.
Allergic diseases are complex and broad in terms of organs affected and
severity, ranging from highly prevalent allergic rhinitis to life-threa-
tening anaphylaxis (Cohen and Zelaya-Quesada, 2002). Progress in the
allergy field started in 1869 when Dr. Charles H. Blackley demonstrated
that pollen was the apparent cause of his hay fever (Taylor and Walker,
1973), and continued throughout the 1900s with the establishment of
immunotherapy using whole allergen extracts as a routine practice by
the 1970′s (summarized in Fig. 1). A need to develop a systematic
nomenclature for allergens became apparent in the early 1980s, when
only few allergens had been identified and allergen names were in-
consistently used in publications. This article focuses on allergen no-
menclature in the context of Immunoglobulin E (IgE)-mediated aller-
gies, directed against apparently harmless substances, mostly proteins
and glycoproteins from diverse biological origins. Allergen sources in-
clude pollen, mites, animal epithelia and saliva, fungi, insect venoms
and a variety of plant and animal foods.
Allergen extracts contain many other proteins and components in
addition to allergenic proteins. The first identified allergenic protein,
antigen E (AgE), was isolated from pollen of short ragweed (Ambrosia
artemisiifolia) by King and Norman in 1962 (Marsh et al., 1981). Other
ragweed allergens identified at an early stage included Ra3 and Ra5
(Marsh et al., 1981). Around the same time, proteins from ryegrass
pollen (Rye I and Rye II, later called Lol p I and Lol p II) were identified as
prominent allergens by Johnson and Marsh as reviewed in Freidhoff
et al. (1986). In the course of this and subsequent discovery work ori-
ginally aiming for a better understanding of HLA-associations with al-
lergic immune responses, the potential of using specific allergenic mo-
lecules for more precise diagnosis and possibly for immunotherapy was
gradually emerging (Yunginger and Gleich, 1972; Baer et al., 1980).
During the past decades, advances in protein biochemistry and mo-
lecular biology have accelerated the discovery and characterization of
allergens, being generated by recombinant DNA technology for a variety
of applications, including basic and clinical research, allergen product
standardization, allergy diagnostics and development of novel ther-
apeutic approaches. Investigation of individual patient sensitization
profiles has recently become possible via application of their sera to solid
phased purified allergens in single assays or on microarrays with over
100 purified allergens, to accurately identify IgE-binding proteins and
sources that likely cause their symptoms. Clear IgE binding to 2S albu-
mins of peanut or soybean or to oleosins in peanut are likely to indicate
higher risks of severe reactions (Beyer et al., 2015; Ebisawa et al., 2013;
Schwager et al., 2017). Measuring specific IgE patterns can also help
guide clinicians to treat patients with allergen immunotherapy (Sastre
et al., 2012). Clinicians seeing patients allergic to bee and wasp venom
may also improve diagnostic and therapeutic success for patients with
so-called double-sensitizations using valuable molecular markers to
prove primary sensitizations to the culprit venom (Seyfarth et al., 2017).
In the future, individual immunotherapeutic reagents and prescriptions
may be available for improved therapy. These developments further
underpin the need for a consistent and unambiguous nomenclature of
allergens. In parallel, the Allergen Nomenclature Sub-Committee has
adapted to these changes by updating the criteria for defining a new
allergen and the information requested in the submission form. This
article provides an update on these criteria and challenges facing the
existing system. Publishing the criteria ensures consistency and trans-
parency of the process. Researchers are strongly encouraged to address
them, with support of appropriate data reported confidentially to the
WHO/IUIS Sub-Committee, to demonstrate evidence of allergenicity in
order to receive an official allergen name prior to publication.
2. The beginning of the systematic Allergen Nomenclature: three
men in a boat 1980
The idea for the current allergen nomenclature system originated from
a discussion among Drs. David Marsh (USA), Henning Løwenstein
Fig. 1. Historical perspective: A) Key discoveries in the allergy field. B) Developments in allergen nomenclature. Important milestones in development of clinical allergy and in
nomenclature are described.
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(Denmark) and Thomas Platts-Mills (UK) during a boat ride on Lake
Constance (Bodensee), Konstanz, Germany, during the 13th Symposium of
the Collegium Internationale Allergologicum in July 1980 (Marsh et al.,
1986; Chapman, 2004). The revised nomenclature system was first de-
scribed in the Bulletin of the World Health Organization by the committee
of clinicians who joined the International Union of Immunological Society
(IUIS) Sub-Committee for Allergen Nomenclature, with David Marsh as
Chair (Marsh et al., 1986). Many of the Sub-Committee scientists listed in
the 1986 publication have been active in the evolution of rules and de-
cisions on proposed allergen nomenclature. Other members have chaired
the Sub-Committee over time (Wayne Thomas, Heimo Breiteneder and
now Richard E. Goodman), with Jørgen N. Larsen pioneering the devel-
opment of a web site, which was refined by John Wise at the University of
Nebraska. In 2017, there are 22 active members and five members at large
(listed on the website). The website http://allergen.org/originally showed
allergens and information as a simple table, while a searchable database
was established in 2007 and entries are since then added as they are
agreed upon by the Sub-Committee.
Allergen names are assigned by the WHO/IUIS Allergen
Nomenclature Sub-Committee through a defined submission process as
described in Section 5. This process ensures that an appropriate, ap-
proved and non-redundant name is assigned to the allergen for any
further publication. The benefit of this nomenclature system is that
allergens are named in a properly documented, consistent and un-
ambiguous manner, creating and maintaining clarity amongst the sci-
entific, clinical and regulatory communities.
3. Evolution of allergen names
During the early 1980′s, the Sub-Committee established guidelines
for naming allergens based on the taxonomic name of the source or-
ganism. Original allergen names comprised the first three letters of the
genus and the first letter of the species epithet (both in italics) followed
by a Roman numeral to indicate the allergen in the chronological order
of isolation from the same source (Marsh et al., 1986). The publication
described the requirements for data that should be provided as pre-
requisite for naming allergens including
- molecular weight (estimated mass by SDS-PAGE or gel-filtration),
- isoelectric point,
- amino acid composition or sequence, and
- immunochemical characterization, i.e. allergen recognition by pa-
tient IgE and/or animal antisera.
Epidemiology of allergens was called for in early publications of the
Sub-Committee in terms of frequency of positive IgE binding from 20 to
30 human subjects. Over time, as biochemical, immunochemical and
biophysical methods have improved, the expectations for description of
allergens have grown and several nomenclature conventions have been
changed including a requirement of fewer subjects.
In 1994, the nomenclature was revised, so that allergen names
would not be in italics (reserved for genes), and the Roman numbers
were replaced by Arabic ones (e.g. Amb a 1, Der p 1) (King et al., 1994).
The 1994 update included a statement that sequence information would
be required for new allergens (described in Radauer et al., 2014). The
focus was on the amino acid (AA) sequence of the protein which is the
relevant target for IgE. However, criteria for acceptance of sequences to
the database have been adjusted over time as methods of protein de-
termination have improved. A few new allergens were identified in a
1995 WHO/IUIS update (King et al., 1995).
In the 1990s, many allergens were being cloned and expressed as
recombinant proteins and that led to the identification of multiple,
highly homologous sequences. Then the WHO/IUIS Allergen
Nomenclature Sub-Committee recognized the need to name homo-
logous allergens in the same organism as either isoallergens or variants
(isoforms), as described below.
4. Current allergen nomenclature conventions
As defined in the 1994 revision, allergen names consist of the first
three letters from the genus, one letter from the species epithet, fol-
lowed by an Arabic numeral. Occasionally, a letter is added to the genus
(Sola for tomato, Solanum lycopersicum, as Sol was used for multiple ant
species, Solenopsis sp.) or to the species (Hel as 1 for a snail Helix aspersa
as Hel a was used for sunflower, Helianthus annuus) abbreviation to
differentiate otherwise identical names of allergens from different
species. Sometimes, the taxonomic name of the species is changed (e.g.
Betula verrucosa became Betula pendula), but the Sub-Committee might
decide to keep the same original allergen name if it has been widely
used in the literature (e.g. Bet v 1 for the major birch pollen allergen).
Allergens from the same source are classified in biochemical groups
(designated by Arabic numeral that contains two digits), usually ac-
cording to the order in which they were identified (e.g. Der p 1 or Bet v
1). When possible, allergens from different species, related up to the
taxonomic level of family or order, that belong to the same biochemical
protein family will be assigned the same number across species.
However, due to the historical naming convention, some allergens of
the same biochemical protein family have been assigned different
numbers (e.g. pectate lyases Amb a 1 and Art v 6, PR-10 proteins Bet v 1
and Ara h 8, or the profilins Amb a 8, Bet v 2, Phl p 12 and Art v 4).
Within each group, allergens can be isoallergens or variants (isoforms)
depending on their amino acid sequence identity. Isoallergens are
homologous allergens that share the following common biochemical
properties: similar molecular size, similar or identical biological func-
tion, if known, and an amino acid sequence identity of at least 67% (as
a guideline not always followed if justified). Each isoallergen may have
multiple forms of highly identical sequences (> 90% identity, typically
differing in only few amino acids), which are designated as variants (or
isoforms). Isoallergens and their variants defined in this way are dis-
tinguished by numerical suffixes following a dot after the allergen
number. The first two numerals 01–99 refer to a particular isoallergen
(e.g. Amb a 1.01 and Amb a 1.02), and the two subsequent numerals
01–99 define each variant of a particular isoallergen (e.g. Amb a 1.0101
and Amb a 1.0102). Generally, allergen names should always be spelled
out in full and partial abbreviation of allergen names (e.g. Ara h 1/2 or
Ara h 1 and 2) is discouraged.
5. Review process by the Allergen Nomenclature Sub-Committee
The review process of a candidate allergen is shown in Fig. 2. The
scientist submitting a protein as a candidate allergen should complete
the submission form (www.allergen.org) and forward it to the Sub-
Committee Chair by email. The scientist may suggest an allergen name
(including isoallergen and variant number) based on current WHO/IUIS
nomenclature.
Each submission is assigned for review to two or three members of
the Sub-Committee, selected by the Chair of the Sub-Committee ac-
cording to their area of expertise. Any possible conflict of interest with a
potential reviewer can be indicated by the scientist submitting the form
on the first page. The submission is held confidential within the Sub-
Committee until a final decision is made. In case of uncertainty re-
garding particular criteria, descriptions or methods used, additional
information may be requested. Final decisions are made by the Sub-
Committee, based on the current criteria for allergen nomenclature, and
communicated to the investigators who should then use the assigned
name in their publication and in sequence databases. The process
normally requires two weeks from submission to review, but may re-
quire longer depending on a need for additional data.
6. Essential criteria for acceptance of a protein as an allergen in
the database
Acceptance of a protein as an allergen in the database essentially
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relies on the demonstration of its presence in the source that causes
allergies, characterization of the protein by standard methods of bio-
chemistry and molecular biology (Section 6.1), and, most importantly,
the proof of specific recognition by relevant human serum IgE (Section
6.2). The main criteria for acceptance of a candidate allergen, sum-
marized in the decision chart of Fig. 3, are:
• Description of the allergenic source, including taxonomic name.
• Information on the purification and characterization of the candi-
date allergenic protein including amino acid sequence.
• Description of the allergic human serum donors used to test IgE
binding to the candidate protein.
• Demonstration of specific IgE binding with five sera of relevant
patients.
Over time, the WHO/IUIS Sub-Committee has refined the criteria
for inclusion of proteins in the allergen database, as methods of testing
by investigators and knowledge of allergen structures have improved
(Chapman et al., 2007, Breiteneder and Chapman, 2014). The database
currently includes 880 allergens, about 100 of which have had their
three-dimensional structure determined (Pomés et al., 2015). Demon-
strated biochemical function and tertiary structure are not necessary to
obtain a name from the Sub-Committee, but may help in the overall
understanding of allergenicity and potential cross-reactivity.
6.1. Analysis of candidate allergens by biochemistry and molecular biology
The WHO/IUIS allergen database includes only proteins and gly-
coprotein allergens. Ideally, the full amino acid and nucleotide se-
quence of the allergen should be provided on the submission form. If
the full sequence is not available (i.e. for purified native allergens that
have not been cloned), a partial amino acid sequence must be de-
termined (i.e. by mass spectrometry).
The apparent MW of the protein should be estimated based on mi-
gration compared to standards in SDS-PAGE, by size exclusion chro-
matography, by mass spectrometry, or by calculation based on the
amino acid sequence. Mass spectrometry determines the absolute mo-
lecular mass and is more definitive than SDS-PAGE, but its use is not a
mandatory requirement.
The amino acid sequence of the protein should be deposited in a
general protein database (UniProt or GenBank Protein) and the acces-
sion number specified in the application form. The experimentally de-
termined protein sequence, as well as the determined DNA sequence,
should be entered in the submission form. If the amino acid sequence is
incomplete (due to gaps for example), each amino acid gap should be
entered as “xxx”. In cases where only a partial sequence was de-
termined by N-terminal or LC–MS/MS sequencing, which is identical to
a published protein sequence from the same species, the accession
number of the published sequence should be added with a clear note in
the submission form. If the sequence has not been published before, the
authors have the option to request that a non-public sequence remains
confidential until publication.
To enable evaluation of potentially confounding data, scientists
submitting a name are encouraged to provide additional information
such as glycosylation state and purity of the protein isolated from the
natural source or recombinant allergen. For glycosylated proteins, al-
though not required, possible involvement of the glycan in IgE binding
could be assessed following deglycosylation or by performing an in-
hibition assay using a high glycan source such as phytohemagglutinin
(PHA) from Phaseolus vulgaris. Alternatively, IgE reactivity with a non-
glycosylated recombinant allergen protein provides evidence that car-
bohydrate binding is not essential for allergen recognition if the re-
combinant protein has been demonstrated to fold like the native al-
lergen. If the protein identity has been verified by monoclonal
antibodies, the identity of the hybridoma and the assay method used
should be described to allow the Sub-Committee to evaluate the quality
and relevance of the data presented. If the cDNA sequence was de-
termined by polymerase chain reaction (PCR) the sequence and position
of primers should be described. If the sequence has already been pub-
lished, the reference should be provided. If the sequence and descrip-
tion was already presented at a scientific conference, the abstract and
poster or relevant presentation slides should be provided.
Finally, IgE-mediated allergies are also induced by small molecules
if bound to carrier proteins (e.g. human serum albumin). These are low-
MW organic compounds such as various drugs (e.g. antibiotics, muscle
relaxants, opioids) and various organic compounds that can act as IgE-
binding haptens and cause clinical reactions (Deak et al., 2016). There
are also certain carbohydrate structures, such as specific plant- or
Fig. 2. Summary of workflow for the submission and evaluation of candidate allergens to the WHO/IUIS Allergen Nomenclature Sub-Committee. In many cases questions are
forwarded to submitters in order to assure an appropriate science-based review. The goal is to provide a decision within two weeks, but sometimes decisions are delayed. Submitters
should contact the Chair if they have questions.
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insect-derived asparagine-linked glycans, commonly called cross-re-
active carbohydrate determinants (CCD) that can bind IgE, but rarely or
never elicit allergic reactions (Van der Veen et al., 1997; Foetisch et al.,
2003; Mari et al., 2008). The carbohydrate structure galactose alpha-
1,3 galactose (alpha-gal), present on many non-primate mammalian
proteins, has recently been found to cause severe delayed IgE-mediated
reactions following consumption of red meat in those who have been
sensitized by salivary proteins from tick bites (Commins et al., 2009;
Commins and Platts-Mills, 2013). Similar relationships between tick
bites and meat allergy have been found in Europe (by the tick Ixodes
ricinus; Hamsten et al., 2013a; Hamsten et al., 2013b; Wilson et al.,
2017), as well as Asia (Chinuki et al., 2016). These glycoproteins are
unusual targets of IgE binding. Since the antibody recognition is di-
rected to the glycan structure rather than the protein structure, they are
not included in the WHO/IUIS database as allergens unless IgE binding
has been demonstrated against the deglycosylated (unglycosylated)
protein.
6.2. Proof of allergenicity of the newly identified proteins
Allergens are usually only accepted in the database if the purified
protein is demonstrated to specifically bind IgE antibodies from at least
five patients allergic to the respective allergen source. Specificity is
demonstrated by lack of IgE binding in atopic and non-atopic control
donors. Exceptions to the patients’ number may be made in particularly
justified cases (such as in the field of occupational allergy or allergens
in novel foods or new products), where it might be difficult to find five
specifically allergic patients to prove allergenicity. In these cases, ad-
ditional proof of allergenicity might then be requested, such as IgE
immunoblots, dot blots, ELISA, basophil activation tests or mediator
release assays (i.e. RBL) with the pure allergen. The IgE binding should
be tested in a described and well controlled assay with the purified
(natural or recombinant) allergen. Data from in vivo provocation of
patients is not required, but adds value in demonstrating mast cell
degranulation. Such tests should only be performed following informed
consent of subjects, ethical review panel approval and appropriately
controlled, sterile antigens.
Proof of allergy to the allergen source is also preferred. In general,
the route of exposure might contribute to identify symptoms. For ex-
ample, the natural route of pollen, animal dander, fungal spores and
airborne occupational allergen exposure is inhalation. Thus, rhino-
conjunctivitis or asthma is the expected clinical outcome. Food aller-
gens should be linked to objective symptoms of oral allergy syndrome,
angioedema of the larynx, symptoms from the gastro-intestinal tract or
systemic symptoms such as urticaria, asthma or anaphylaxis after
consumption of the food. Insect bites or stings should generally include
urticaria plus angioedema as well as other possible systemic reactions.
However, exceptions will always occur. Skin symptoms after ingestion
of allergens are quite common, and the same is true for respiratory
symptoms. Patients with urticaria might not be the best candidates for
skin testing. For some allergens (e.g. from mites) it is difficult to relate
clinical symptoms to natural exposure. Also, some individuals with high
levels of allergen specific IgE or skin test reactivity are asymptomatic
upon natural exposure (Abraham et al., 2007). Therefore, in some cases
larger samples might be required to demonstrate the association with
clinically relevant allergy.
Sensitization and/or elicitation of an allergic response to the source
(allergen extract) may be demonstrated in vitro by basophil activation
or in vivo through inhalation, ingestion, intradermal injection, prick-to-
prick tests or mucosal contact if performed under institutional review
board guidance and following ethical approval.
Positive reactions should be based on criteria such as at least three
mm wheal size for allergen extracts greater than the negative SPT
control or greater than an established cut-off (e.g. three times the
standard deviation of negative control subjects by in vitro IgE binding
for ELISA) for extracts or the purified protein.
Fig. 3. Essential criteria for allergen acceptance.
The primary questions of the submission form are
designed to allow the reviewers to understand what
was done, how complete the characterization of the
allergen candidate was, indicating the protein se-
quence and physical characteristics, the selection of
serum donors, tests for IgE binding as well as biolo-
gical tests (SPT or BAT). The scientists submitting the
form should provide enough information to demon-
strate that their protein is most likely to be an al-
lergen.
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7. Challenges to the Allergen Nomenclature Sub-Committee
7.1. Revision of allergen names
Due to the risk of confusion and the fact that some names have
already been published, the WHO/IUIS Sub-Committee generally takes
a conservative position regarding changing allergen names. However,
some allergen names have been revised or further specified as the ori-
ginal characterization was incomplete or associations were determined
to be wrong based on new evidence.
1. The seed storage proteins of soybean provide two examples. The Gly
m 5 protein is a complex of three beta-conglycinin subunits that
were not characterized at the time the allergen name was assigned.
One subunit is now known as beta-conglycinin alpha (67 kDa), the
second as beta-conglycinin alpha’ (71 kDa) and the third as beta-
conglycinin beta (50 kDa) as described by Holzhauser et al. (2009).
The alpha- and alpha′- subunits are approximately 82% identical.
The sequence of the beta-subunit is only 76% identical to the two
alpha subunits. The three subunits fit together to form a trimeric
structure. However, different ratios of Gly m 5 subunits form mul-
timeric associations in protein bodies of the soybean (Maruyama
et al., 2002). IgE from soybean allergic subjects may bind to one,
two or three subunits of Gly m 5. The protein complex was originally
named Gly m 5, but following analysis of intact complexes, various
combinations of beta-conglycinins were identified to form the
multimeric complexes (Holzhauser et al., 2009). Therefore, the in-
dividual subunits were finally named as isoallergens Gly m 5.01, Gly
m 5.02 and Gly m 5.03 in 2009, with minor variants (e.g. Gly m
5.0301 and Gly m 5.0302).
2. Similarly, glycinin (Gly m 6) was also named with an understanding
that the whole protein has a complex hexameric structure, made of
combinations of different subunits (Nielsen et al., 1989). With fur-
ther gene and protein characterization, it was recognized that at
least five genes encode the subunits (Nielsen et al., 1989) and the
allergen can be an arrangement of these five proteins which have
individual IgE binding properties (Holzhauser et al., 2009), and
which were renamed as five isoallergens in 2009.
3. Bovine milk casein was originally named Bos d 8, but full char-
acterization has demonstrated that it is composed of complexes
made up of four primary proteins (Willis et al., 1982). One is now
called Bos d 9 (alpha S1 casein) as described by Nagao et al. (1984).
The other caseins are defined as Bos d 10 (alpha S2 casein), Bos d 11
(beta casein) and Bos d 12 (kappa casein) with IgE binding defined
by Natale et al. (2004). These proteins have high sequence diversity
and they form complexes associated with calcium ions involved in a
micellar structure. IgE antibodies from cow’s milk allergic subjects
may bind to any combination of these subunits. Additional IgE
binding from cow’s milk allergic individuals involves beta-lacto-
globulin, alpha-lactalbumin and for some, IgG or lactoferrin.
4. There are examples of homologous allergen domains or whole al-
lergens from grass pollen of related species (Lolium sp, Dactylon sp,
and Phleum sp.) with proteins sharing considerable sequence identity
which are difficult to assign to either the same or a different group.
For example, Lol p 2 and Lol p 3 share approximately 60% identity.
Dag g 2 is 60% identical to Lol p 3, 65% identical to Dac g 3 and
65% identical to Phl p 2, which is within the differences in isoforms
accepted by the Sub-Committee. However, both grass pollen groups
2 and 3 were kept separate as there is high conservation across
species and a marked reduction in sequence identity between group
2 and group 3 proteins among grass pollen. There is also some
homology to group 1 beta-expansin proteins of the group 2 and 3
grass pollens though the major group 1 beta-expansin grass pollen
allergens including Lol p 1 are much longer proteins and share little
IgE cross-reactivity (Devanaboyina et al., 2014).
5. Two examples exist of allergens that were renamed due to high
sequence identities. One is the ragweed allergen Amb a 2 that has a
high amino acid sequence identity to group 1, and was therefore
renamed as Amb a 1.0501. The other is a seed storage glycinin al-
lergen in peanut, Ara h 4 that is> 90% identical to Ara h 3.0101
and it was therefore renamed as Ara h 3.0201 in 2012.
7.2. Difficulty in naming certain allergens
Some allergens are difficult to name for different reasons.
7.2.1. Complexity
The major cat allergen Fel d 1 (Morgenstern et al., 1991), has a
crystal structure similar to that of secretoglobin (Kaiser et al., 2007).
This allergen is a tetrameric protein formed by two heterodimers of
chain 1 and chain 2, which are encoded by separate genes. Unlike Gly m
5 and Gly m 6 mentioned above, two different proteins are under one
allergen name, Fel d 1.0101 (King et al., 1995). The allergen has a
unique structure and there is no evidence of IgE cross-reactivity with
secretoglobulins of other species (Hilger et al., 2014). A revision of this
name in the future is possible but unlikely, given the widely spread use
of Fel d 1 in the scientific community.
7.2.2. Low amino acid identity
Glutathione S-transferases (GST) from cockroach are structurally
and functionally related and belong to different GST classes. GSTs at-
tach a glutathione molecule to highly different substrates leading to the
high GST diversity regarding function and sequence. The question is
whether allergens with a similar biochemical function deserve the same
group number, despite highly different sequences. It seems that iden-
tical group numbers within a species should generally alert scientists to
the possibility of cross-reactivity. Nevertheless, cockroach GSTs from P.
americana and B. germanica were assigned to the same group 5, despite
their low amino acid identity (15.7% between Bla g 5 and Per a 5; way
under the suggested threshold of 67% to be in the same group as iso-
allergens). More recently the Sub-Committee is trying to reserve the
same number for homologous proteins from different species.
7.2.3. Hydrophobic nature of some allergen parts
Oleosins are hydrophobic allergens with an unusual hydrobophic
core and few hydrophilic sections responsible for IgE antibody binding.
Assignment of names to oleosins was difficult, because the molecular
structure was taken into consideration to dissect and compare only the
hydrophilic portions of the protein. Other proteins challenging to
analyze for the purpose of assigning an allergen name include vitello-
genins of chicken (Walsh et al., 1988). Vitellogenins are encoded as
polyproteins and expressed in the liver as phospholipoproteins, then
transported via blood and taken up and processed in egg yolk. The
process includes proteolysis into independent shorter proteins and one
has been listed now as an allergen by WHO/IUIS (Gal d 6) (De Silva
et al., 2016). Similar cases were reported earlier for fish roe proteins
(Shimizu et al., 2009). The proteins are complex and assignment of IgE
binding has often been to the holoprotein.
7.3. Assignment of names to isoallergens or variants (isoforms)
Isoallergens or variants (isoforms) are currently defined based on
their amino acid sequence identity, but they might be originated in
different ways (Table 1). In some cases, information on whether they
are encoded by separate but related genes or the same gene with
polymorphisms could assist in the identification. For example, there are
7 gene loci that encode beta expansins in Johnson grass pollen, in-
cluding Sor h 1. The two allergens Sor h 1.0101 and Sor h 1.0201 are
encoded by separate gene loci (Campbell et al., 2015). Similarly, the
cockroach allergens Bla g 1.0101 and Bla g 1.0201 are listed as iso-
allergens due to the high sequence similarity, but recent genomic evi-
dence suggests they are distinct gene products (Fig. 4). Investigators are
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not required to provide information on gene structure or location, but
as this information becomes available it might help to improve the
understanding of protein structures and potential name assignments.
New isoallergens will only be accepted in the database if IgE binding
has been demonstrated to the isoallergen. New variants will only be
accepted if there is justified evidence that the variant is expressed in the
organism and tissue causing allergies. The use of PCR based cloning
techniques and genome analysis has increased the potential identifi-
cation of erroneous sequences. The committee would like investigators
to sequence multiple clones from independent experiments and to
provide accurate information on the source and methods used to de-
termine sequences. Ideally, the existence of the protein in the natural
source should be verified by mass spectrometry or N-terminal sequen-
cing with sufficient length to verify that the protein sequence matches
the nucleic acid sequence. Additional information for inclusion into the
database are the characterization of the purified recombinant variant,
confirmation of the source and identity of the organism, as well as IgE
reactivity with the recombinant protein.
7.4. Cross-reactivity might impair the identification of source-specific
allergens
Considerations include whether proteins that are homologs of
allergenic proteins are allergens themselves, binding IgE and if so,
whether patients show symptoms upon exposure. Antibody cross-re-
activity can occur with only few amino acids (1–3) in common between
homologous proteins (Glesner et al., 2017), but it does not necessarily
translate into clinical cross-reactivity. Serum IgE cross-reactivity has
been observed between PR-10 related allergens from birch pollen (Bet v
1), apple (Mal d 1) and other plant-derived foods. However, birch
pollen is usually the primary sensitizer and elicitor of the allergic im-
mune response, whereas cross-reactive IgE binding to Mal d 1 is often of
lower avidity, or may involve a single IgE epitope and therefore may or
may not be clinically relevant for individual patients. Similarly, there
are patient-specific patterns of IgE cross-reactivity to fish parvalbumins
coupled with clinical sensitivity to some fish, but not to other fish
species (Kuehn et al., 2014) or to chicken (fish-chicken syndrome)
(Kuehn et al., 2016). There are numerous examples of reactivity to
homologous allergens from multiple allergen sources that can be ex-
plained by IgE cross-reactivity. For example, there is cross-reactivity
among lipocalins Can f 6 of dog dander, Fel d 4 of cat dander and Equ c
1 of horse dander (Nilsson et al., 2012). Each of these three allergens
can act as primary sensitizer, co-sensitizer or cross-reacting molecule,
depending on the exposure profile of the patient. Cross-reactivity with
Can f 6 was responsible for a clinically relevant positive specific IgE to
dog dander in a horse allergic patient (Jakob et al., 2013). Data on
Table 1
Possible origins of isoallergens, variants and other types of allergen heterogeneity.
Type of heterogeneity Origin Characteristics Known examples in the
Allergen Nomenclature
database
Dispersed amino acid sequence
variability. Named as isoallergens
or variants, depending on level of
sequence divergence.
Allelic One isoallergen/variant per haplotype.a Der f 2; Bet v 1 variants
are in part allelicDifferential IgE antibody recognition of isoallergens
may occur but is less likely for variants.
Multigene family Multiple isoallergens/variants, encoded by different
genes per haplotype, may be present per organism.a
Bet v 1
Differential IgE antibody recognition of isoallergens
may occur but is less likely for variants.
Ara h 2
Size and/or charge distribution Posttranslational modifications such as addition
of carbohydrate, phosphate groups, hydroxy-
proline, C-terminal proteolytic cleavage or other
moietiesb
Each individual proteins may contain multiple
postranslationally modified allergen forms.
No examples
Differential IgE antibody recognition of glycoforms
may occur.
Chemical composition Chemical modification of the allergenb Modification of the allergen during airborne transport
(for aeroallergens), storage and processing (for food
allergens), or preparation of extracts, e.g. oxidization,
reactions with polyphenols, Maillard reaction during
roasting of foods.
No examples
Block differences: amino acid sequence
differences in segment/s of the
protein.
Different protein cleavage Each individual contains multiple differentially
cleaved forms.
Hev b 6.02 and Hev b 6.03
IgE antibody recognition may be affected depending
on epitope distribution.
Alternative mRNA splicing None yet identified for allergens. No examples
Modular differences: Different subunit
(entire gene product) composition.
Alternative subunit composition Each individual contains multiple allergen forms,
depending on subunit combinations.
Gly m 5, Gly m 6
IgE antibody recognition may be affected depending
on epitope distribution.
a Polyploidy (more than two haplotypes) will further increase the number of genes (each of which can harbor different allelic isoallergens/variants).
b This kind of modification does not lead to different isoallergens or variants.
Fig. 4. Genetic and chemical structure of group 1 Blattela germanica
allergens. A) Bla g 1 isoallergens are encoded by different genes (in
italics), which are composed of fully and partially repeated genetic ele-
ments indicated by the boxes. Blue rectangles represent regions with
76–99% sequence identity to either the yellow or green rectangle. The
defined allergens at WHO/IUIS only partially cover the full open reading
frame. B) The structure of the second half of Bla g 1.0101 was de-
termined (4JRB, Mueller et al., 2013). The yellow and green coloring
corresponds to the portion of gene similarly colored in A. The long lin-
kers between structured elements suggest the full protein will resemble
beads on a string. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
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sequence and structural similarity combined with serum IgE binding
must be carefully evaluated as demonstrated by the studies of IgE
binding and allergy of Ole e 1 (olive pollen allergen), Fra e 1 (ash pollen
allergen) and Pla a 1 (English plantain pollen allergen). The overall
structures are similar as could be predicted to some extent by sequence,
yet there is a clear gradation of IgE binding among patients, with un-
ique clinical responses (Stemeseder et al., 2017). Thus, sequence or
structural information alone is judged insufficient to name a protein as
an allergen.
7.5. Is the Sub-Committee naming too many allergens?
The WHO/IUIS Allergen Nomenclature database lists 17 allergens in
peanut Arachis hypogaea, 31 in house dust mite Dermatophagoides far-
inae, 20 in Dermatophagoides pteronyssinus and 23 in Aspergillus fumi-
gatus. Some of those are likely minor allergens or only hypothetical
proteins from cDNA (such as Tri a 42 and Tri a 43 in wheat). Some
simply have a low IgE binding capacity for some subjects that is only
detected when presented at high concentration by in vitro assays, and
might not contribute to the IgE binding to the source because the al-
lergen might not be well represented in the allergenic material or al-
lergenic extracts (Casset et al., 2012). Others, like Der p 23, turned out
to be significant allergens (Weghofer et al., 2013). In contrast, some
allergens such as Der f 22, which shows a low identity (∼40%) to Der f
2 and no publications demonstrating evidence of IgE binding or re-
activity in the literature for nearly 10 years, probably should not have
been accepted by the Sub-Committee. Der f 22 will be re-reviewed and
might be removed from the database unless new evidence is uncovered
by the Sub-Committee in the future. The Sub-Committee is considering
removing other allergens from the database. Some allergens (such as
the tomato allergens Sola l 2), bind IgE only through carbohydrates,
and this IgE is not clinically relevant. In other cases, IgE binding to high
concentrations of purified proteins that are naturally low in abundance
can mislead the assessment of a protein as an allergen. In these situa-
tions, the use of non-glycosylated recombinant proteins at concentra-
tions mimicking natural protein abundance would assist in assessing
IgE binding to the desired protein.
7.6. Integration of big data from ‘omics’ research
The application of massively parallel DNA and transcriptome se-
quencing, proteomics, bioinformatics, mass-spectrometry and protein
chemistry processes coupled with sensitive high or multi-allergen array
immunoassays is markedly increasing the capacity for data generation
and discovery. Through studies of whole allergen source tran-
scriptomics and genomics, it is evident that multiple gene copies exist in
a given source for a single protein family that contains allergenic as
well as non-allergenic members. Thus not all putative allergen gene
sequences actually encode allergens. This may be for a variety of rea-
sons including that some gene loci are pseudogenes. Not all “genes” are
transcribed, translated and processed in the relevant tissue at the time
when or location where sensitized individuals are exposed. Examples of
this include the greater number (six of seven) genes encoding Johnson
grass pollen beta-expansin proteins that can be confirmed within the
pollen proteome, whilst only two of these gene loci encode IgE reactive
proteins isoforms. Similar findings have been observed and/or pro-
posed for the multiple beta-expansin gene loci of rice (Devis et al.,
2017) and Sorghum bicolor (Paterson et al., 2009) and profilins of rice
(Devis et al., 2017). Other examples are the polcalcin protein family
with the allergen Phl p 7, parvalbumins of fish (e.g. Gad m 1) and the
PR-10 family, which includes Bet v 1 from birch pollen (Erler et al.,
2011).
Currently, there is good knowledge of many protein families that
contain allergens (Radauer et al., 2008). Yet many proteins within the
families are not known to cause allergy. Although there are numerous
publications that attempt to predict allergens using bioinformatics with
genomic and transcriptomic data, detection of the proteins in the al-
lergenic source material is essential. Predictive models of allergenicity
based on sequence identity are not reliable due to the wide variations in
the percentage of amino acid sequence identity that is associated with
cross-reactivity, and the lack of knowledge regarding the actual epi-
topes for these proteins. Other factors are important for allergenicity,
such as abundance and structural stability for food allergens or solu-
bility for aeroallergens. Thus the WHO/IUIS Sub-Committee strives to
stimulate appropriate characterization of allergenic proteins and de-
monstration of IgE binding from appropriate human volunteers, to
demonstrate that a given protein is likely to cause allergy.
7.7. Assignment of names before publication
The goal of the WHO/IUIS Allergen Nomenclature Sub-Committee is
to assign names to allergens before publication. The purpose is to as-
sociate a name with the original publication. However, the danger of
this process is that the data used to characterize the allergen have not
been evaluated through peer-reviewed publication. In the last four
years, the Sub-Committee has been asking for more comprehensive
information prior to accepting a candidate as an allergen, and the
submission form has been modified accordingly to reflect that and it
will likely continue evolving. One goal of this publication is to en-
courage investigators to meet the need for more relevant information
prior to submission.
Journals cannot rely on reviewers to make sure that correct allergen
nomenclature is used in publications unless it is emphasized by the
editorial office and forms part of the “Instructions to Authors”. Allergen
names are sometimes published that do not comply with the official
WHO/IUIS nomenclature, causing inconsistencies in the literature.
Currently, journals (especially journals that are not only allergy fo-
cused) still sometimes do not publish names accepted by the Sub-
Committee. To help improve the correct assignment and use of allergen
names, the WHO/IUIS Allergen Nomenclature Sub-Committee has
contacted in 2017 the editorial offices of the main journals that publish
allergen studies, to request the implementation of a policy requiring the
use of the official allergen nomenclature in their publications. There has
been a positive response from the journals and most of them have al-
ready implemented such a change of the instructions to authors.
Some allergens not recognized and listed by the WHO/IUIS have
been published in journals indexed in PubMed. Even more commonly,
genomics, transcriptomics and proteomics projects are assigning pro-
teins in sequence databases (e.g. GenBank) with “allergen-like” names
or even listing proteins or genes with a WHO/IUIS-like name, however,
without having provided evidence-based data on protein allergenicity.
Authors are encouraged to submit such allergens to the Sub-Committee
for its consideration and having an official name assigned.
8. Other allergen sequence and structure databases
Several publicly available allergen databases exist with different
purposes, strengths and weaknesses (reviewed by Radauer, 2017). The
WHO/IUIS allergen nomenclature database provides a systematic and
official allergen nomenclature for many allergens. Allergome (www.
allergome.org) comprises a large amount of partially filtered informa-
tion and references of allergens, public references for the proteins and
links to many reference sources. AllergenOnline (www.allergenonline.
org) is a peer-reviewed risk assessment tool for food safety and includes
allergens from all sources (Goodman et al., 2016). AllergenOnline is
updated annually with reviews of individual proteins and data of IgE
binding and clinical responses after publication of data on the allergens
and allergenicity. The COMPARE database (comparedatabase.org)
hosted by the Health and Environmental Sciences Institute was derived
from the AllergenOnline.org database (> 99% of entries in COMPARE)
and shows the same “year adopted” for entries as in the AllergenOnline
database. It does not yet have a sequence search system, but is intended
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to eventually be a risk assessment tool similar to AllergenOnline. The
Structural Database of Allergenic Proteins database (SDAP, fermi.utm-
b.edu) is linked to a structural database source and is intended as a risk
assessment tool. The Immune Epitope Database (IEDB, www.iedb.org)
provides information on T-cell and B-cell epitopes as well as MHC
binding proteins of many proteins including pathogens, viruses, bac-
teria and some allergens. The AllFam database (www.meduniwien.ac.
at/allfam) focuses on protein families of allergens based on information
from publications, from WHO/IUIS, AllergenOnline and Pfam data-
bases. Users of these databases should understand the information and
intent of each of these databases and their limitations.
9. Future directions and new initiatives
A The Sub-Committee has had recognition and some financial support
from the International Union of Immunological Societies (IUIS) for a
number of years. In 2016 the Sub-Committee gained additional
support from the European Academy of Allergy and Clinical
Immunology (EAACI) that recognized it as one of its committees. In
2017, support was gained from the American Academy of Allergy,
Asthma and Immunology (AAAAI). The time and effort needed to
maintain the database and for members to provide careful review of
submissions is considerable. All members act on a voluntary basis,
without financial compensation.
B Allergen database hosting. From 2007 through 2017 the WHO/IUIS
database was hosted without charge in the Department of Food
Science & Technology, on a Food Allergy Research and Resource
Program server at the University of Nebraska-Lincoln (USA). The
Who/IUIS database was transferred to the EAACI computer server in
November 2017 and the cost of maintaining the database will be
shared by the IUIS, EAACI and AAAAI. The WHO/IUIS Allergen
Nomenclature Sub-Committee is now an official committee in the
EAACI organization.
C The Sub-Committee is reviewing and improving available informa-
tion and tools on the database to help researchers compare their
newly identified candidate allergens in the context of the database.
The Sub-Committee welcomes suggestions that may be submitted to
the Chairman or Sub-Committee members.
D As advances are made in technology of gene sequencing, tran-
scriptomics and proteomics, more questionable allergen candidates
are being submitted to the WHO/IUIS Sub-Committee and other
sequence databases. The Sub-Committee encourages that scientists
revise and remove “unproven” allergens from protein databases
(GenBank Protein, and UniProt). However, it is important to note
that as a committee on nomenclature, the mission is to provide a
framework for consistent allergen identification and not to pass
judgement on whether an allergen is a major, mid-tier, or minor
allergen. The scientific discussion about the merits of a particular
allergen is simply facilitated by accurate nomenclature to identify
the molecule in question.
E How the Allergen Nomenclature Sub-Committee responds to and
evaluates the increasing numbers of putative allergens will be an
increasing challenge. Not all putative allergen-like sequences are
demonstrably allergenic. Processes and criteria for assessing aller-
genicity might need to be continually evaluated and revised.
Research and critical thinking will need to address the capacity to
assimilate many different data sources into useful and clinically
relevant information that aids the diagnosis and treatment of al-
lergic patients.
F A full online review process analogous to the ones for manuscripts
can be envisioned. Name assignments to allergen candidates are
performed by the Chair of the Sub-Committee and two to three re-
viewers. Currently the WORD file submissions are maintained on the
server. Once an online entry form is developed, the submissions
should be handled with less chance of manual errors, although the
committee will review all entries before they become public.
10. Conclusions
The WHO/IUIS Allergen Nomenclature Sub-Committee serves as an
expert professional group that reviews supporting evidence of aller-
genicity of proteins, assigns names and manages an official list of re-
cognized allergens. The Sub-Committee also clarifies the understanding
of qualities of allergen molecules and focuses current thinking about the
criteria for allergenicity of proteins from molecular, biochemical, in
vitro immunoassay-based methods as well as clinical perspectives.
Investigators are encouraged to follow the criteria set by the Sub-
Committee to provide evidence-based data on allergenicity prior to
submitting an allergen. Ultimately, whether a protein is an allergen for
a particular patient depends on the level of sensitisation, exposure and
clinical allergy status. As the introduction of allergen components has
had major impact on analytical sensitivity, specificity and allergy di-
agnosis (Matricardi et al., 2016), allergen nomenclature will remain
and become increasingly important in the context of the application of
the wide array of “omics” technologies in allergy research. In the future,
the WHO/IUIS Allergen Nomenclature Sub-Committee will continue to
provide expertise and criteria to evaluate evidence of the specificity of
IgE binding for candidate allergens. These criteria will most likely
evolve as additional data are generated from new technologies. Re-
cently, there has been an explosion of “Big Data”, from various “omics”
techniques that will impact on the submissions to the database. The
continued activities of the WHO/IUIS Allergen Nomenclature Sub-
Committee are an important component of the review process to assign
names to allergens before peer-reviewed publication. These activities
help scientists and reviewers to focus on relevant data supporting
characterization of allergens and IgE binding, and stimulate more rig-
orous review of clinical implications applied to allergens. The assign-
ment of reliable names to allergens is useful for pharmaceutical com-
panies making diagnostic and therapeutic materials for patients, helps
provide information as the medical field of allergology continues to
move from using crude extracts to the use of individual allergens.
However, database users should remember that a WHO/IUIS name
designation relies on data provided by the scientist submitting the
candidate allergens, before peer-review publication. The Sub-Com-
mittee contributes to improve continued interactions of scientists and
clinicians in the effort to improve diagnoses, therapy and risk avoidance
for those who have specific allergies.
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